Tag Archive for: Angiotech Pharmaceuticals

Jeffrey Gross, PhD, joins Angiotech Pharmaceuticals as Vice President of Engineering

Life Science Partner recruits former Group Director, Biologics Research and Development of Medtronic Sofamor Danek.

Life Science Partner announces the recruitment of Jeffrey Gross, PhD, former Group Director of Biologics R & D at Medtronic Sofamor Danek in Memphis, Tennessee, as Vice President of Engineering. 

Angiotech is the world leader in the emerging field of drug-eluting medical devices and biomaterials.   With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Gross will lead the discovery team to capitalize upon Angiotech’s considerable intellectual property portfolio to create breakthrough products.

In Jeff’s previous role at Medtronic, he led large multidisciplinary teams of scientists and engineers in the development of heart valves and, more recently, in innovative, next-generation biological products for spine and cranial surgeons.

“Jeff has a broad cardiovascular product background and is well-grounded in biological and mechanical medical device development,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He knows how to lead cross-functional teams across multiple technologies to bridge the combination product development divide successfully.”

In his role as Vice President of Engineering, Jeff will provide strategic and tactical direction for engineering R & D across multiple complex device platforms within numerous sites and divisions of Angiotech.  His teams will bridge the continuum from product concept through design review phases, and pilot manufacturing and transfer.

Jeff earned his B.S. in Mechanical Engineering at the Georgia Institute of Technology and his M.S in Biomedical Engineering from the University of Houston.   He received his PhD in Biomedical Engineering (Biofluid Mechanics) from the University of Memphis in Memphis, Tennessee.

/0 Comments/by

Chris Dennis to join Angiotech Pharmaceuticals as Senior Vice President, Sales and Marketing

Life Science Partner announces recruitment of former Global President of J&J’s OrthoNeutrogena Company, a Division of Ortho-McNeil Pharmaceutical, Inc.

Life Science Partner announces the appointment of Chris Dennis, a senior sales, marketing and general management executive, to Angiotech Pharmaceuticals, Inc. as the Senior VP of  Sales and Marketing.   

Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

In Dennis’ most recent role at OrthoNeutrogena, a pharmaceutical and aesthetic device company, he was responsible for the overall strategy and business growth initiatives.  In his previous position at Janssen Ortho, Inc., a Canadian pharmaceutical company, he served as Vice President of Marketing and Sales where he managed a wide range of prescription medications. 

Mr. Dennis also held the position of President, LifeScan Canada Ltd. (medical devices), where he oversaw the sales, marketing and distribution of diagnostic products for people with diabetes.   He also held a number of sales and management roles at McNeil Consumer Products, a J&J company, and Bristol Myers Products Canada.

At Angiotech, Dennis will be focused on building a global sales and marketing organization and commercialization strategy that includes the company’s sales and market capability in the five identified markets of Ophthalmology, Wound Closure, Vascular, Biopsy and Aesthetics.  He will have the responsibility for building near-term strategies and subsequent revenues from innovating technologies existing within each of these product areas.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Learn More About Chief Executive Functions
/0 Comments/by

Tom Weber to join Angiotech Pharmaceuticals as Senior Director of Analytical Chemistry

Life Science Partner recruits former Director, Analytical Research and Development of Celator Pharmaceuticals Corporation

Life Science Partner announces the appointment of Tom Weber, a pharmaceutical R & D executive, to Angiotech Pharmaceuticals, Inc., as the Director of Analytical Chemistry.

Angiotech is a world leader in the emerging field of drug-eluting medical devices and biomaterials. With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Weber will lead the analytical chemistry team to capitalize upon Angiotech’s considerable intellectual property portfolio to create break-through products.

At Celator Pharmaceuticals, an early-stage biopharmaceutical company developing new combination therapies to treat cancer, Weber led the analytical and bioanalytical development of new products through validation, technical transfer and clinical stage product testing.   As experienced pharmaceutical scientist, he was previously a senior research and development officer in a several early, mid and development stage pharmaceutical companies.

“Weber brings a wealth of experience in the development of new drugs, drug delivery, drug-congugates and drug-device products which will enable him to immediately contribute to Angiotech’s ongoing projects as well as future developmental programs,” noted Cindi Roberts, Vice President at Life Science Partner.

Weber will lead strategic and tactical direction to the Chemistry group within global R&D across multiple complex device platforms including novel pharmaceutical agents and local delivery technology as well as novel combination product development involving local delivery of device platforms.

Weber received his Bachelor of Arts degree in Chemistry and Physics from Gustavus Adolphus College in St. Peter, Minnesota and his PhD in Chemistry from the University of Minnesota.

/0 Comments/by

Angiotech Pharmaceuticals Recruits Tim Lowinger as Vice President, Pharmaceutical Science and Chemistry

Life Science Partner recruits Tim Lowinger, PhD, global leader in chemistry research and development to help propel proprietary products

Life Science Partner announces the recruitment of Tim Lowinger, PhD, formerly vice president, chemistry research at Bayer Healthcare, to lead Angiotech Pharmaceuticals’ newly formed division of pharmaceutical science and chemistry. Angiotech is the world leader in the emerging field of drug-eluting medical devices and biomaterials.  

With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Lowinger will lead the discovery team to capitalize upon Angiotech’s considerable intellectual property portfolio to create break-through products.

Lowinger is well-positioned to lead this team, as he has considerable experience at Bayer in chemistry development as well as in leadership of global teams including medicinal and analytical chemistry departments – developing drugs from hit generation through lead optimization.

“Tim is a triple threat,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He is the prototype of the top-shelf pharmaceutical chemist.  He has built and led global teams – spanning the U.S., Japan and Germany.  Tim has the ability to see beyond the lab bench to find solutions that can improve patients’ lives.”

Joining Bayer as a research scientist in 1993, Lowinger was responsible for all chemistry efforts within the cancer exploratory research team. He was promoted to the head of the chemistry department at Bayer Yakuhin, where he established a new cancer research center and built Bayer’s first Japanese chemistry research facility.  After establishing a global research center, he was relocated to corporate headquarters in Wuppertal, Germany, to become responsible for the virology therapeutic area.  In 2003, he assumed responsibility for the global chemistry organization as Vice President, Chemistry Research based in West Haven, CT.

Lowinger earned his B.Sc. (Chemistry) and PhD (Organic Chemistry) at the University of British Columbia, Vancouver.  He was a Merck Post-doctoral Fellow at Ohio State University under the leadership of Professor Leo Paquette as his advisor.

/0 Comments/by

Angiotech Pharmaceuticals Recruits Andrew Penman to Become Vice President, Preclinical Development

Life Science Partner recruits global leader in preclinical development to help accelerate product creation and add pharmaceutical expertise

Life Science Partner announces the recruitment of Andrew Penman, PhD, formerly president, preclinical development at Aptuit (a spin-out of Quintiles Transnational) to lead Angiotech Pharmaceuticals newly formed division of preclinical development. 

Angiotech is the world leader in the emerging field of drug-eluting medical devices and biomaterials.    With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Penman will lead the preclinical development team to capitalize upon Angiotech’s considerable intellectual property portfolio to create breakthrough products.

A well-respected manager of preclinical development, Penman was responsible  for a global team of 350 people worldwide and service revenues of $55m generated through contract preclinical services in the Kansas City and UK locations.  The Company was formed by the spin-out of the preclinical group of Quintiles, a company in which he led the DMPK and Bioanalysis group.

“Andy is an excellent manager and preclinical scientist,” noted Cindi Roberts, vice  president of Life Science Partner.  “His experience in the contract-services business of preclinical drug development has honed his business and organizational skills.”

Penman joined Quintiles upon the acquisition of Pharmacia by Pfizer.  Within the pharmaceutical industry, he was director, drug metabolism and biodisposition at the Pfizer Skokie site.  He honed his skills in early drug development as President of  Cephac Europe, a 100-scientist bioanalytic division of Aster-Cephac.  His recruitment to Quintiles in 2003 was a return to the company he joined in 1995 in its Scotland-based bioanalysis group.

Penman earned his B.Sc. in Chemistry at Heriot-Watt University in Edinburgh and his Ph.D. at University of Kent in Canterbury.

/0 Comments/by